ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

Research output: Contribution to journalArticlepeer-review


  • Malcolm Ranson
  • Lisa A Hammond
  • Mark Kris
  • Andrew Tullo
  • Vince Miller
  • Steve Averbuch
  • Judy Ochs
  • Charles Morris
  • Andrea Feyereislova
  • Helen Swaisland
  • Eric K Rowinsky

Colleges, School and Institutes


To investigate the tolerability, pharmacokinetics, and antitumor activity of the oral, selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 in patients with solid malignant tumors.


Original languageEnglish
Pages (from-to)2240-50
Number of pages11
JournalJournal of Clinical Oncology
Issue number9
Publication statusPublished - 2002